首页> 外文OA文献 >Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

【2h】

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

机译：用于使用Lapatinib Ditosylate加入Capecitabine的临床推荐，用于患有先进或转移性HER2阳性乳腺癌的患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Raymond D SNYDER; Frances M BOYLE; Arlene CHAN; Paul S CRAFT; Richard DE BOER; Paul N MAINWARING; Nicole J McCARTHY; Nicholas R WILCKEN;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer [J] . Raymond D SNYDER, Frances M BOYLE, Arlene CHAN, Asia-Pacific journal of clinical oncology . 2009,第1期

机译：拉帕替尼二甲苯磺酸盐加卡培他滨治疗晚期或转移性HER2阳性乳腺癌患者的临床建议
2. Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study [J] . Hiroji Iwata, Hirofumi Fujii, Norikazu Masuda, Breast cancer . 2015,第2期

机译：拉帕替尼联合卡培他滨治疗HER2阳性晚期或转移性乳腺癌患者的疗效，安全性，药代动力学和生物标志物研究：来自51位日本患者的临床研究结果
3. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea [J] . Jungsil Ro, Sohee Park, Sung- Bae Kim, BMC Cancer . 2012,第1期

机译：拉帕替尼和卡培他滨治疗HER2阳性转移性乳腺癌脑转移患者的临床结局：韩国一项开放标签扩展研究
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Efficacy safety pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study [O] . Hiroji Iwata, Hirofumi Fujii, Norikazu Masuda, -1

机译：拉帕替尼联合卡培他滨治疗HER2阳性晚期或转移性乳腺癌患者的疗效安全性药代动力学和生物标志物发现：来自51位日本患者的临床研究结果
7. Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study [O] . 2015

机译：拉帕替尼联合卡培他滨治疗HER2阳性晚期或转移性乳腺癌患者的疗效，安全性，药代动力学和生物标志物发现：来自51位日本患者的临床研究结果

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅